Investor Library

StemRIMIR LibraryTimely Disclosure Information
September 19, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Director  
September 6, 2023 Timely Disclosure Information StemRIM Announces Patent Registration (US) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy (Dilated Cardiomyopathy, Ischemic Cardiomyopathy, and Hypertensive Cardiomyopathy)  
September 4, 2023 Timely Disclosure Information StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction  
July 31, 2023 Timely Disclosure Information StemRIM Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide (HMGB1 Peptide) Targeting Acute Ischemic Stroke (Japan)  
July 25, 2023 Timely Disclosure Information StemRIM Announces the Initiation of Global Late Phase 2 Clinical Trials for Redasemtide (HMGB1 Peptide) Targeting Acute Ischemic Stroke (Europe, China)  
July 18, 2023 Timely Disclosure Information StemRIM Announces Patent Registration (Korea) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction  
May 24, 2023 Timely Disclosure Information StemRIM Announces Orphan Drug Designation of Regeneration-Inducing Medicine Redasemtide (HMGB1 peptide)  
May 22, 2023 Timely Disclosure Information StemRIM Announces Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease (Additional Report)  
May 18, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Patent Registration (Taiwan) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction  
April 28, 2023 Timely Disclosure Information StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke  
April 11, 2023 Timely Disclosure Information [Delayed] StemRIM Announces Preliminary Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease  
April 11, 2023 Timely Disclosure Information [Delayed] Notice of Earnings Forecasts for the Fiscal Year Ending July 31, 2023  
April 11, 2023 Timely Disclosure Information [Delayed] StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke